Novavax Inc's Customers Performance

Name: Novavax Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

NVAX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


NVAX's Source of Revenues		During the corresponding time, Novavax Inc saw a revenue deteriorated by -76.3 % year on year, sequentially revenue fell by -59.36 %. While revenue at the Novavax Inc 's corporate clients • List of NVAX Customers

for the same period Novavax Inc revnue deteriorated by -76.3 % year on year, sequentially revenue fell by -59.36 %.

• List of NVAX Customers

Novavax Inc's Business Units


Product	107.68 %	of total Revenue
Licensing, royalties, and other	1.68 %	of total Revenue
Nuvaxovid sales	16.86 %	of total Revenue
Supply sales	90.83 %	of total Revenue
Sanofi Royalties	7.41 %	of total Revenue
Upfront Fee Amortization	36.75 %	of total Revenue
Milestone Amortization	16.43 %	of total Revenue
Support Services	0.6 %	of total Revenue
Reportable	346.07 %	of total Revenue
United States	237.27 %	of total Revenue
Europe	37.5 %	of total Revenue
Rest of the world	71.29 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Novavax Inc's Comment on Sales, Marketing and Customers

The company serves customers and markets including strategic partners Takeda, Serum Institute of India (SII), Sanofi, and Pfizer. Sanofi is involved in the commercialization, development, technology transfer, and sales of COVID-19 vaccine products, influenza-COVID-19 combination vaccines, CIC products, and adjuvant products, with milestone and royalty payments structured accordingly. Pfizer holds a License and Option Agreement for the use of Matrix-M™ in up to two disease areas, involving upfront, milestone, and royalty payments. Takeda is engaged through a collaboration and exclusive license agreement, with an amended agreement dated April 29, 2025.

Novavax Inc’s Comment on Sales, Marketing and Customers

NVAX's Stock Performance relative to it's Customers

NVAX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Novavax inc	1,668.80	596.34	-87.84	749
SUBTOTAL	0.00	0.00	0.00	-

Sources: Novavax inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Novavax inc’s corporate clients.
For your research, we’ve provided 9 tables on Novavax inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.